← Back to all trials
Recruiting
NCT05731843
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
Conditions: Healthy Volunteer Study
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 32
Sponsor: Atea Pharmaceuticals, Inc.
Location: Canada
Summary
Drug-drug interaction study of Ruzasvir and Bemnifosbuvir
Eligibility Criteria
Inclusion Criteria:Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug.Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2.Willing to comply with the study requirements and to provide written informed consent.Exclusion Criteria:Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2.Abuse of alcohol or drugs.Use of other investigational drugs within 28 days of dosing.Concomitant use of prescription medications, or systemic over-the-counter medications.Other clinically significant medical conditions or laboratory abnormalities.
Source: ClinicalTrials.gov (NCT05731843). StuddyBuddy aggregates publicly available trial information.
